Abstract
The aim of this study was to test for a potential anticarcinogenic effect of Celergen, a marine derivative devoid of traceable amounts of inorganic arsenic, on cell proliferation, cell cycle progression and apoptosis in the HepG2 human liver cancer cell line. Celergen significantly inhibited the proliferation of cancer cells in a dose-dependent manner while limiting the cell cycle progression at the G1 phase and significantly inducing apoptosis. Further examination showed that Celergen enhanced expression of the p21(CIPl1WAF1), GADD153 genes and downregulated the c-myc gene. These results suggest that Celergen exerts promising chemopreventive properties to be further investigated.
MeSH terms
-
Anticarcinogenic Agents / administration & dosage
-
Anticarcinogenic Agents / isolation & purification
-
Anticarcinogenic Agents / pharmacology*
-
Apoptosis / drug effects
-
Aquatic Organisms
-
Biological Products / administration & dosage
-
Biological Products / isolation & purification
-
Biological Products / pharmacology*
-
Cell Cycle / drug effects
-
Cell Proliferation / drug effects
-
Cyclin-Dependent Kinase Inhibitor p21 / genetics
-
Dose-Response Relationship, Drug
-
Down-Regulation / drug effects
-
G1 Phase / drug effects
-
Gene Expression Regulation, Neoplastic / drug effects
-
Genes, myc / genetics
-
Hep G2 Cells
-
Humans
-
Liver Neoplasms / drug therapy*
-
Transcription Factor CHOP / genetics
Substances
-
Anticarcinogenic Agents
-
Biological Products
-
Cyclin-Dependent Kinase Inhibitor p21
-
DDIT3 protein, human
-
Transcription Factor CHOP